Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is between 18-55 years of age, inclusive.~2. Subject meets the following criteria for a diagnosis of BED:~   * Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).~  * The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.~  * Marked distress regarding binge eating.~  * The binge eating occurs, on average, at least 2 days a week for 6 months.~  * The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.~3. Subject is consistently able to swallow a capsule.~Exclusion Criteria:~1. Subject has current diagnosis of bulimia nervosa or anorexia nervosa.~2. Subject is receiving psychotherapy or weight loss support within the past 3 months.~3. Subject has used psychostimulants to facilitate fasting or dieting within the past 6 months.~4. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease.~5. Subject has abnormal thyroid function.~6. Subject initiated treatment with a lipid lowering medication within the past 3 months.~7. Subject has a history of moderate or severe hypertension.~8. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder.~9. Subject has glaucoma.~10. Subject is female and pregnant or nursing.~11. Subjects who have had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine dimesylate (Type: EXPERIMENTAL): Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
- Placebo (Type: PLACEBO_COMPARATOR): Administer one capsule orally daily at approximately 7:00 AM.

Based on this trial design, predict the completion outcome and termination type (if applicable).